Before becoming LegalReader's Editor-in-Chief, Jay W. Belle Isle worked as a freelance copywriter with clients on four continents. Jay has a degree in Business Administration from Cleary University and a Juris Doctor from Thomas M. Cooley Law School. Jay has also worked as a contracts administrator for a DOD contractor specializing in vehicle armor.


Verdict in for Walden v Chrysler in Fiery Death of 4-year-old Remi Walden

Earlier I wrote about Chrysler-Fiat’s CEO and his less-than-compassionate response during deposition in this case. I’ll bet he regrets that robotic and idiotic stance today. The verdict is in and the jury has awarded the Walden family $150 million dollars. The breakdown is $30M for pain and suffering and $120M for value of Remi Walden’s


California Works to Stop ‘Kill All Gays’ Ballot Proposal

Before I begin this analysis, I have to take a brief moment to warn you: What you are about to read is absolutely a current initiative in California. If the recent RFRA debacle in Indiana rubbed you the wrong way, this one is going to walk up to you and punch you in the throat.


UPDATE: Proposed Changes to Indiana RFRA Law Would Return Hoosier Hospitality

Cooler heads may prevail in Indiana returning the famous Hoosier hospitality to its former prominence after the recent Religious Freedom Restoration Act sparked national protest. Business, sports and civic leaders were against the divisive RFRA from the beginning fearing it would result in open discrimination of the state’s LGBTQ community and a substantial loss of


Landmark Verdict in Talc Related Asbestos Case Upheld

The $1.6M verdict in Kaenzig v. Charles B. Chrystal Co. involved a rarely reported on case of mesolthelioma caused by asbestos in cosmetic-grade talc. Typical asbestos cases involve industrial disease aspects. In fact, plaintiff’s counsel in Kaenzig wasn’t aware of any other talc-related verdicts. It’s believed that this case is the first of its kind





Hepatitis C Drugs Combined with Antiarrhythmic Drug can Cause Serious Slowing of Heart Rate

Patients treating hepatitis C with Harvoni (ledipasvir/sofosbuvir) or Sovaldi (sofosbuvir) in conjunction with another direct acting antiviral such as the investigational drug daclatasvir or Olysio (simeprevir) and also treating arrhythmia with amiodarone are at serious risk of developing symptomatic bradycardia. This dangerous combination has already resulted in one patient death due to cardiac arrest and